IP Library Granted Patent US 12,029,764
Granted Patent B2
US 12,029,764 · App. 16/618,148 · Granted Jul 9, 2024

Compositions and methods for obtaining organoids

Inventors: Charis-Patricia Segeritz (Vancouver, CA); Ryan Conder (Vancouver, CA); Michael Riedel (Vancouver, CA)
Assignee: STEMCELL TECHNOLOGIES CANADA INC.
A61K35/38A61L27/3633A61L27/3813A61L27/54A61L2300/434A61L2430/28G01N33/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,029,764
App. No.
16/618,148
Granted
Jul 9, 2024
Kind
B2
Abstract

A method for obtaining epithelial organoids is provided. In one embodiment, the method comprises culturing one or more epithelial ducts, epithelial duct fragments and/or epithelial stem cells isolated therefrom in contact with an extracellular matrix in the presence of a basal medium, wherein the medium is free of FGF and/or nicotinamide. Organoids obtained by the methods described herein, and uses thereof, are also provided.

Claims (12)

1. A medium for obtaining an epithelial organoid, the medium comprising a basal medium and a Wnt agonist, wherein the medium is (a) free from FGF and/or nicotinamide and (b) free from an inhibitor of BMP signalling and wherein the medium is capable of supporting the organoids for 5 or more passages.

2. The medium of claim 1 , wherein the Wnt agonist is selected from one or more of CHIR99021, Wnt, Wnt3a, Norrin, R-Spondin 1, R-Spondin 2, R-Spondin 3, R-Spondin 4 and a GSK inhibitor.

3. The medium of claim 1 , further comprising one or more of a B27 component, a N2 component and/or N-Acetylcysteine.

4. The medium of claim 1 , further comprising an extracellular matrix, optionally wherein the extracellular matrix concentration ranges between 0.1 to 50% (v/v).

5. The medium of claim 4 , wherein a concentration of the extracellular matrix is about 0.1% (v/v) or less.

6. A medium for obtaining an epithelial organoid, the medium comprising a basal medium and one or more of a B27 component, a N2 component, and/or N-Acetylcysteine, wherein the medium is:

i) free of FGF and/or nicotinamide, free of an activator of the Wnt-beta-catenin pathway, free of a member of the EGF family and free of an inhibitor of BMP signaling, or

ii) free of FGF and/or nicotinamide, free of a member of the EGF family, free of an inhibitor of BMP signaling, and supplemented with one or more activators of the Wnt-beta-catenin pathway, or

iii) free of FGF and/or nicotinamide, free of an inhibitor of BMP signaling, and supplemented with one or more activators of the Wnt-beta-catenin pathway and one or more members of the EGF family, and

wherein the medium supports the organoids for 5 or more passages.

7. The medium of claim 1 , further comprising one or more members of the EGF family.

8. The medium of claim 7 , wherein the one or more members of the EGF family is EGF.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2019
From: SEGERITZ, CHARIS-PATRICIA; CONDER, RYAN; RIEDEL, MICHAEL
To: STEMCELL TECHNOLOGIES CANADA INC.
Reel/Frame 051136/0647 →
Continuity (2)
Provisional Application 62512138 · May 29, 2017
Related Publication 20200188443A1 · Jun 18, 2020
Cited By (1)
US 12,370,222